Figure 4. In vivo efficacy of preemptive HB22.7-SAP treatment. (A, B) Nude mice were subcutaneously injected with 5 x 106 Raji cells. Twenty-four h later, designated as day 0, mice were randomly separated into three treatment groups (n = 8–10 per group) consisting of PBS, free HB22.7 (0.6 mg/kg) plus free SAP (0.36 mg/kg) and HB22.7-SAP (1 mg/kg). The dose of free HB22.7 and free SAP was equivalent to those of each component in the HB22.7-SAP conjugate. Starting on day 0, treatments were administered by intraperitoneal injection weekly for a period of three weeks (indicated by arrows). (A) Tumor volume was calculated using the formula (L × W2)/2. (B) Body weight was measured twice a week and the percent of starting weight was calculated.